ViaCell, Inc.

Based in Cambridge, Massachusetts, ViaCell focuses on the research, development and commercialization of cellular therapies in the United States and Singapore. The company develops a pipeline of proprietary umbilical cord blood-derived and adult-derived stem cell product candidates as treatments for cancer, cardiac disease and diabetes. The company was acquired by PerkinElmer, Inc. in November 2007. (Nasdaq: VIAC) (www.viacellinc.com)